致：香港交易及結算所有限公司 公司名稱: 微泰醫療器械（杭州）股份有限公司 (於中華人民共和國注冊成立) 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 呈交日期: 2026年1月7日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02235 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 169,175,842 | RMB | | 1 RMB | | 169,175,842 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 169,175,842 | RMB | | 1 RMB | | 169,175,842 | | 2. 股份分類 | 普通股 ...

微泰医疗-B(02235)发布公告，于2026年1月5日该公司斥资23.17万港元回购3万股，回购价格为每股7.59- 7.77港元。 ...

格隆汇1月5日丨微泰医疗-B(02235.HK)公告，1月5日耗资23.2万港元回购3万股。 ...

智通财经APP讯，微泰医疗-B(02235)发布公告，于2026年1月5日该公司斥资23.17万港元回购3万股，回 购价格为每股7.59-7.77港元。 ...

如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02235 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年12月29日 | | 1 ...

Core Viewpoints - The company announced that its LinX continuous glucose monitoring (CGM) system has recently received market approval in Brazil, further strengthening its international expansion strategy [1] - The CGM product is expected to continue its growth trend in the domestic market through both online and offline channels, while overseas markets show significant potential for revenue growth due to a low revenue base and increasing market share [1][3] - The company reported a net loss of only 2.29 million yuan in the first half of 2025, nearing breakeven, with expectations of achieving profitability by 2026 [1][3] Event Summary - On December 23, 2025, the company announced that its LinX CGM system received market approval in Brazil for both adults and children, enhancing its market presence in Latin America [1] Market Performance - The company reported a 218% increase in GMV during the "Double Eleven" shopping festival, with the second-generation CGM device's shipment volume increasing by 622.8% and new user numbers rising by 300% [2] - The company ranked first in sales on major e-commerce platforms, indicating effective brand promotion [2] R&D Progress - The company is making steady progress in its R&D pipeline, with clinical trials for the AiDEX CGM system for pregnant women completed and the Equil insulin pump system's clinical trial enrollment in Europe finished [2] - The company is exploring AI applications in CGM through internal team formation and collaborations with leading research institutions, aiming to innovate diabetes management [2] Revenue and Profit Outlook - The company expects continued high revenue growth in 2026, with a projected revenue of 5.31 billion yuan in 2025, representing a year-on-year growth of 53.78% [3] - The company anticipates achieving breakeven in 2025 and profitability in 2026, supported by stable gross margins and cost optimization measures [3]

Core Viewpoint - MicroTech Medical-B (02235.HK) announced the grant of a total of 3.3 million shares to 51 qualified individuals under its share incentive plan adopted on December 24, 2025, with the shares pending acceptance by the grantees [1] Company Summary - As of December 30, 2025, MicroTech Medical-B closed at HKD 7.93, up 2.72%, with a trading volume of 57,000 shares and a turnover of HKD 444,000 [1] - The stock has a market capitalization of HKD 1.282 billion, ranking 18th in the medical device II industry [1] Investment Ratings - The majority of investment banks have a buy rating for MicroTech Medical-B, with one bank issuing a buy rating in the last 90 days [1] - CITIC Securities recently provided a buy rating for MicroTech Medical-B [1] Key Financial Metrics - Return on Equity (ROE): -1.36%, compared to the industry average of -4.85%, ranking 19th [1] - Market capitalization: HKD 1.282 billion, with the industry average at HKD 5.097 billion, ranking 18th [1] - Revenue: HKD 441 million, with the industry average at HKD 1.2 billion, ranking 17th [1] - Net Profit Margin: -0.93%, compared to the industry average of -19.0%, ranking 17th [1] - Gross Margin: 51.66%, with the industry average at 54.03%, ranking 17th [1] - Debt Ratio: 10.8%, compared to the industry average of 29.53%, ranking 5th [1]

（原标题：微泰医疗-B(02235)授出合共330万股奖励股份） 智通财经APP讯，微泰医疗-B(02235)发布公告，根据其于2025年12月24日采纳的股份激励计划，公司于 2025年12月30日向51名合资格人士(承授人)授出合共330万股奖励股份。奖励股份由公司于联交所上市 的普通股(H股)组成，且该授出须待承授人接纳后方可作实。 ...

微泰医疗-B(02235)发布公告，根据其于2025年12月24日采纳的股份激励计划，公司于2025年12月30日 向51名合资格人士(承授人)授出合共330万股奖励股份。奖励股份由公司于联交所上市的普通股(H股)组 成，且该授出须待承授人接纳后方可作实。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部份內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 MicroTech Medical (Hangzhou) Co., Ltd. 微 泰 醫 療 器 械（ 杭 州 ）股 份 有 限 公 司 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股份代號： 2235） 根據股份激勵計劃授出獎勵股份 本公告乃微泰醫療器械（杭州）股份有限公司（「本公司」及其附屬公司，「本集 團」）根據香港聯合交易所有限公司（「聯交所」）證券上市規則（「上市規則」）第 17.06A條作出。 本公司董事（「董事」）會（「董事會」）欣然宣佈，根據其於2025年12月24日採納的 股份激勵計劃（「股份激勵計劃」），本公司於2025年12月30日向51名合資格人士 （「承授人」）授出合共3,300,000股獎勵股份（「獎勵股份」）。獎勵股份由本公司於 聯交所上市的普通股（「H股」）組成，且該授出須待承授人接納後方可作實。 – 1 – （ 已授出獎勵股份概要載 ...